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AbstrACt
Objectives Studies that use national datasets to 
evaluate the management of older women with breast 
cancer are often constrained by a lack of information 
on patient fitness. This study constructed a frailty index 
for use with secondary care administrative records and 
evaluated its ability to improve models of treatment 
patterns and overall survival in women with breast 
cancer.
Design Retrospective cohort study.
Participants Women aged ≥50 years with oestrogen 
receptor (ER) positive early invasive breast cancer 
diagnosed between 2014 and 2017 in England.
Methods The secondary care administrative records 
frailty (SCARF) index was based on the cumulative deficit 
model of frailty, using International Statistical Classification 
of Diseases, Injuries and Causes of Death, 10th revision 
codes to define a set of deficits. The index was applied to 
administrative records that were linked to national cancer 
registry datasets. The ability of the SCARF index to improve 
the performance of regression models to explain observed 
variation in the rate of surgery and overall survival was 
evaluated using Harrell’s c- statistic and decision curve 
analysis. External validation was performed on a dataset of 
similar women diagnosed in Wales.
results The SCARF index captured 32 deficits that 
cover functional impairment, geriatric syndromes, 
problems with nutrition, cognition and mood, and 
medical comorbidities. In the English dataset (n=67 
925), the prevalence of frailty in women aged 50–69, 
70–79 and ≥80 years was 15%, 28% and 47%, 
respectively. Adding a frailty measure to regression 
models containing age, tumour characteristics and 
comorbidity improved their ability to: (1) discriminate 
between whether a woman was likely to have surgery 
and (2) predict overall survival. Similar results were 
obtained when the models were applied to the Welsh 
cohort (n=4 230).
Conclusion The SCARF index provides a simple and 
consistent method to identify frailty in population level 
data and could help describe differences in breast 
cancer treatments and outcomes.
IntrODuCtIOn
UK- based population level studies have 
demonstrated wide variation in the treatment 
and outcomes of older women with early 
invasive breast cancer (EIBC).1 2 Differences 
in how health services manage older women 
with decreased levels of fitness are often 
cited as a key factor contributing to this vari-
ation.1 2 This has been difficult to investigate 
using routinely collected national datasets for 
breast cancer because they contain limited 
information on patient fitness.3 Studies have 
commonly adopted a measure of comorbidity 
burden (eg, Charlson Comorbidity Index 
(CCI))1 2 4 to account for different levels of 
fitness, but this is not ideal because ageing 
is a multidimensional concept that spans 
strengths and limitations of this study
 ► The secondary care administrative records frailty 
(SCARF) index was based on the cumulative deficit 
model of frailty and shares a similar construct to the 
Canadian Study of Health and Aging Frailty Index and 
the electronic Frailty Index.
 ► The study used population- based cohorts of women 
with breast cancer from England and Wales, with the 
English dataset being used to develop the SCARF in-
dex and the Welsh dataset being used for external 
validation.
 ► The deficits used in the SCARF index were defined 
using the International Statistical Classification of 
Diseases, Injuries and Causes of Death, 10th revi-
sion diagnosis codes recorded in the English and 
Welsh hospital administrative databases.
 ► A limitation of the study was its complete case anal-
ysis, with 16% of records excluded because of miss-
ing values in key variables.
 ► This study evaluated the SCARF index within a spe-
cific disease rather than the general population.
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functional ability, physiology and social well- being.5 
Therefore, in order to better understand the reasons for 
variation between older and younger women in treat-
ments and outcomes for EIBC, measures that capture the 
multiple aspects of ageing are required.
The notion of biological age has evolved to describe 
the physiological differences among people of the 
same chronological age and is strongly linked to the 
concept of frailty.6 7 Frailty is described as a dynamic 
and heterogeneous manifestation of age- related decline 
in physiological reserve and increased vulnerability to 
stressors.8–10 While frailty is associated with comorbidity, 
it is recognised as a distinct geriatric syndrome that is 
potentially modifiable.5 However, there is no consensus 
on how to measure frailty and numerous instruments 
have been developed and used in different populations 
and healthcare settings.8 11 12 The Comprehensive Geri-
atric Assessment (CGA) is one method that is widely 
recommended by geriatric professional bodies.6 13 The 
CGA covers groups of domains: cognition/mood, nutri-
tion, functional status, geriatric syndromes, comorbidity 
and polypharmacy.6 Each CGA domain is individually 
assessed for appropriate interventions, and because no 
single assessment method is defined for each domain, 
results from different settings may not be compa-
rable.6 13 Various frailty instruments have also been devel-
oped for screening patients and identifying those who 
would benefit from a more comprehensive assessment, 
but a review of 28 highly cited instruments reported 
considerable heterogeneity between the measures and 
the thresholds used to categorise patients as frail or 
non- frail.14 For these reasons, it is unsurprising that 
population- based databases have been slow to incorpo-
rate the collection of frailty data items.
Various attempts have been made to create a frailty 
measure suitable for use within national datasets. Recently, 
in the UK, four frailty indices have been developed: two 
using primary care data (electronic Frailty Index (eFI),15 
Q- frailty)16 and two using administrative hospital data 
(frailty score17 and hospital frailty risk score).18 All four 
indices adopt the ‘cumulative deficits’ model of frailty,19 
which conceptualises frailty as an increasing number 
of problems in different physiological systems that can 
present as clinical signs or symptoms, physical or cognitive 
impairments, or diseases.20 However, these indices are not 
easily applicable to the population- based datasets avail-
able from UK cancer registration services. For example, 
the calculation of the primary care Q- frailty index uses 
information on medication and biochemical results that 
are not collected in UK cancer registration datasets.16 
Indices derived from administrative hospital datasets can 
be more readily applied to UK cancer registration data. 
Yet, current indices are limited in their coverage of frailty 
domains17 and may overestimate the prevalence of frailty 
due to a methodological assumption of a ‘frail cluster’ in 
hospital admissions.18 Additionally, the performance of 
these indices have not been evaluated in subgroups such 
as patients with cancer.
The aim of this study was to construct a frailty index 
using data available from the cancer registration services 
in England and Wales and evaluate its performance as a 
descriptor of biological age in women with breast cancer. 
In particular, the study evaluated the ability of the frailty 
index to improve the performance of regression models 
to explain: (1) patterns of primary surgery and (2) 3- year 
survival in women aged ≥50 years with oestrogen receptor 
(ER) positive EIBC.
MethODs
Data source
The study was undertaken as part of the National Audit 
of Breast Cancer in Older Patients (NABCOP)21 and 
used pseudonymised patient- level datasets provided by 
the National Cancer Registration and Analysis Service 
for England and Wales Cancer Network for Wales. The 
linked datasets covered women aged ≥50 years diagnosed 
by National Health Service (NHS) breast cancer units in 
England (n=124) and Wales (n=6) and provided data on 
patient demographics, tumour information, as well as 
treatment details. Additional information was provided 
by extracts from routine hospital admission databases 
for NHS hospitals (Hospital Episode Statistics (HES) 
for England and Patient Episode Database for Wales 
(PEDW)). Full details of the NABCOP cohort are detailed 
in the 2019 annual report.3 Data quality and complete-
ness of the variables used in analysis were comparable 
between English and Welsh datasets.3
study population and definitions
This study used the NABCOP datasets to create a cohort 
of women aged ≥50 years with new unilateral oestrogen 
receptor (ER-) positive early stage (Union for Inter-
national Cancer Control (UICC) TNM staging classi-
fication, seventh edition: stage 1 – 3a) invasive breast 
cancer (International Statistical Classification of Diseases, 
Injuries and Causes of Death, 10th revision (ICD-10)22 
code: C50) diagnosed between 1 January 2014 and 31 
December 2017 in an NHS hospital in England or Wales 
(n=85 210).3 Women with no linked hospital administra-
tive dataset record (n=5 543; 6.5%) or missing data for 
key analysis variables (n=7 512; 8.6%) were excluded.
Information on patient demographics (age at diag-
nosis and deprivation) and tumour characteristics were 
obtained from the cancer registration datasets. Area- level 
socioeconomic deprivation was measured using the Index 
for multiple deprivation (IMD), with the IMD values 
for their geographical area in Wales23 and England24 
converted to quintiles. Comorbidity burden was derived 
from the hospital administrative datasets using the Royal 
College of Surgeons Charlson Comorbidity Index (CCI), 
excluding malignancy,4 using a look back period of 2 
years from date of breast cancer diagnosis.25
Primary surgery was defined as the first surgical proce-
dure performed within 6 months of diagnosis, as recorded 
in HES or PEDW. Surgical procedures were described 
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box 1 Inclusion criteria for deficits in the secondary care 
administrative dataset frailty (sCArF) index
Inclusion criteria for deficits in the SCARF index
1. Deficits describe a patient’s health status rather than a reflection 
of the local service provisions in the secondary sector, for example, 
prolonged inpatient stay for rehabilitation.
2. The prevalence of a deficit increases with chronological age and 
does not saturate too early (the saturation point is defined as preva-
lence >50% in persons aged 70+ years).
3. The population prevalence of the deficit should be >0.5% to avoid 
inclusion of rare or poorly recorded deficits.
4. As a group, deficits within the SCARF index should cover all the 
domains of the Comprehensive Geriatric Assessment (CGA).*
*Excluding polypharmacy.
in the datasets using Office of Population Censuses and 
Surveys (OPCS) procedure codes, from which the study 
distinguished between breast conserving surgery (OPCS 
codes: B28, excluding B28.4 and B28.6) and mastectomy 
(any B27 code). Women were defined as not having 
surgical treatment if there was no record of these proce-
dures in the 6 months after diagnosis in HES or PEDW.
Survival information was derived from the Civil Regis-
tration/Mortality data (previously known as the Office for 
National Statistics death register), which contains infor-
mation on cause and date of death. Time to death was 
defined as the interval between date of diagnosis and date 
of death (in days). English women who were alive at the 
end of follow- up were censored on the final date of vital 
status assessment (27 January 2019). The final assessment 
date were not available for women in Wales, so women 
who were alive were censored on the day after the last 
reported date of death (19 September 2018). Median 
follow- up time was calculated in relation to the potential 
follow- up time of all women using reverse Kaplan- Meier 
estimate.26
Construction of the secondary care administrative records 
frailty (sCArF) index
The cumulative deficit model of frailty19 was adopted as 
the basis for the index, with each frailty deficit defined 
using ICD-10 diagnosis codes.22 We chose to limit the 
derivation of the index to information available from 
hospital administrative datasets and not use information 
from cancer registration data, so that it can be applied to 
studies that only have access to routine hospital datasets. 
Hence, it was referred to as the SCARF index.
The initial stage of development involved a review 
of the deficits used in existing population- level frailty 
indices.15–19 27 28 The review highlighted that the majority 
of indices adapted the original 92 deficits in the Cana-
dian Study of Health and Aging Frailty Index.19 27 This 
approach was also used by the eFI,15 which was developed 
and validated in the UK primary care setting15 29 30 and 
which has been incorporated into the English general 
practitioner summary care record for clinical use.31 
Consequently, the initial list for the SCARF index was 
based on the 36 deficits used by the eFI so that it shared 
a similar construction and thus may be a complementary 
instrument in the secondary care setting.
The subsequent stages of the development process are 
outlined below.
1. Identification of administrative data and ICD-10 codes 
for each frailty deficit.
Diagnostic codes for each deficit were identified 
through a search of the ICD-10 system and examina-
tion of other ICD-10 derived indices.17 18 This process 
was also informed by cross- referencing potential ICD-
10 codes with the primary care Read codes used in the 
eFI, although there is not a simple mapping between 
the two classifications. Two independent authors (YJ 
and TR) inspected the final cohort of ICD-10 and ad-
ministrative dataset codes for clinical validity.
2. Exploration of deficit prevalence within English pa-
tient cohort.
The initial SCARF index ICD-10 coding framework was 
applied to the HES records of the English women with 
breast cancer. The process involved checking the 20 
diagnostic data fields in any patient record from the 
date of cancer diagnosis up to 2 years prior18 25 and 
enabled an initial estimate of the prevalence of each 
deficit to be derived. Each frailty deficit was then evalu-
ated against a set of criteria for inclusion of the deficit 
in an index (Box 1), adapted from Searle et al32 and 
Clegg et al15 and those that failed to meet the criteria 
were dropped.
3. Calculation of the SCARF index and categories from 
the deficit profile.
The SCARF index for a patient was calculated as the 
number of deficits present divided by the total number 
in the index. The SCARF index was also stratified into 
four levels of fitness as follows: fit=0–1 deficit (index: 
0–0.05), mild frailty=2–3 deficits (index: 0.06–0.11), 
moderate frailty=4–5 deficits (index: 0.12–0.18) and 
severe frailty=6 or more deficits (index: ≥0.19).
evaluation of the sCArF index’s performance
Frailty is closely related to comorbidity but they are both 
independent concepts of ageing.5 In this study, the degree 
of association between the CCI (as a measure of comor-
bidity) and the SCARF index (as a measure of frailty) was 
evaluated using the Pearson’s correlation coefficient.33 
A correlation value of r>0.8 describes a strong positive 
correlation between two factors.34
The SCARF index was evaluated separately on women 
diagnosed in England and Wales due to the different 
constructs of administrative data sources. Within the 
English HES database, each record corresponds to the 
time a patient is under the care of the same consul-
tant and contains up to 20 ICD-10 diagnosis codes (a 
single admission can consist of one or more consultant 
episodes). The Welsh PEDW database is not as rich in 
diagnostic information. Each record corresponds to a 
single admission and allows up to 14 ICD-10 codes to be 
stored. These differences between the two datasets was a 
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Table 1 Baseline tumour characteristics of women diagnosed with ER- positive early invasive breast cancer between 2014 
and 2017 in England and Wales by age group at diagnosis
England (internal validation) Wales (external validation)
Age group at diagnosis (n (%))
Total
Age group at diagnosis (n (%))
Total50–69 years 70–79 years ≥80 years 50–69 years 70–79 years ≥80 years
Total number of women 44 624 14 862 8 439 67 925 2 812 984 434 4 230
Invasive grade
  G1 9 539 (21) 2 490 (17) 1 323 (16) 13 352 770 (27) 208 (21) 69 (16) 1 047
  G2 26 184 (59) 9 304 (63) 5 511 (65) 40 999 1 585 (56) 602 (61) 290 (67) 2 477
  G3 8 901 (20) 3 068 (21) 1 605 (19) 13 574 457 (16) 174 (18) 75 (17) 706
Tumour size (T stage)
  1–20 mm (T0–1) 29 426 (66) 8 314 (56) 3 485 (41) 41 225 1 921 (68) 550 (56) 163 (38) 2 634
  21–50 mm (T2) 13 505 (30) 5 947 (40) 4 522 (54) 23 974 779 (28) 407 (41) 242 (56) 1 428
  51+mm (T3) 1 693 (4) 601 (4) 432 (5) 2 726 112 (4) 27 (3) 29 (7) 168
Nodal status (N stage)
  N0 32 573 (73) 10 850 (73) 6 414 (76) 49 837 2 306 (82) 813 (83) 377 (87) 3 496
  N1 10 494 (24) 3 375 (23) 1 725 (20) 15 594 403 (14) 143 (15) 50 (12) 596
  N2 1 557 (3) 637 (4) 300 (4) 2 494 103 (4) 28 (3) 7 (2) 138
HER2 status
  Positive 4 380 (10) 1 215 (8) 676 (8) 6271 300 (11) 90 (9) 41 (3) 431
  Negative 37 028 (83) 12 543 (84) 6 993 (83) 56 564 2 512 (89) 894 (91) 393 (97) 3 799
  Borderline 3 216 (7) 1 104 (7) 770 (9) 5 090 – – –
IMD status
  1 – most deprived 6 812 (15) 2 014 (14) 1 239 (15) 10 065 451 (16) 154 (16) 59 (14) 664
  2 8 042 (18) 2 548 (17) 1 541 (18) 12 131 524 (19) 175 (18) 89 (21) 788
  3 9 221 (21) 3 107 (21) 1 809 (21) 14 137 599 (21) 191 (19) 105 (24) 895
  4 10 412 (23) 3 618 (24) 1 968 (23) 15 998 573 (20) 211 (21) 77 (18) 861
  5 – least deprived 10 137 (23) 3 575 (24) 1 882 (22) 15 594 665 (24) 253 (26) 104 (24) 1 022
Charlson Comorbidity Index
  0 40 751 (91) 12 133 (82) 5 604 (66) 58 488 2 623 (93) 864 (88) 296 (68) 3 783
  1 2 955 (7) 1 796 (12) 1 508 (18) 6 259 150 (5) 83 (8) 81 (19) 314
  2 697 (2) 625 (4) 735 (9) 2057 33 (1) 25 (3) 34 (8) 92
  3+ 221 (0) 308 (2) 592 (7) 1121 6 (0) 12 (1) 23 (5) 41
SCARF index*
  Fit 38 682 (87) 10 713 (72) 4 405 (52) 53 800 2 507 (89) 757 (77) 232 (53)
  Mild frailty 3 897 (9) 2 224 (15) 1 380 (16) 7 501 216 (8) 131 (13) 89 (21)
  Moderate frailty 1 670 (4) 1 367 (9) 1461 (17) 4498 73 (3) 73 (7) 59 (14)
  Severe frailty 375 (1) 558 (4) 1193 (14) 2126 16 (1) 23 (2) 54 (12)
*Classification of the SCARF index: fit=0–1 deficit (index: 0–0.05), mild frailty=2–3 deficits (index: 0.06–0.11), moderate frailty=4–5 deficits (index: 0.12–0.18) and severe frailty=6 or 
more deficits (index: ≥0.19).
ER, Oestrogen receptor; HER2, human epidermal growth factor receptor 2; IMD, Index for multiple deprivation; SCARF, secondary care administrative records frailty.
key consideration in fitting the regression models to both 
the English and Welsh cohorts, because depth of coding 
available could affect the performance of a frailty index 
that relies on counting the cumulative number of deficits.
The explanatory power of the SCARF index was evalu-
ated for two different outcome variables: the likelihood of 
surgery and survival. To examine the index’s performance 
to predict the likelihood of women not receiving surgery 
for unilateral ER- positive EIBC, a series of multivariable 
multilevel logistic regression models were developed. The 
models included a random intercept for each NHS trust 
to account for the possible correlation between patient 
characteristics within organisations. Patient and tumour 
characteristics were included in the baseline model 
(model 1): deprivation quintile, tumour grade,human 
epidermal growth factor receptor 2 (HER2) status, 
tumour size (T stage) and nodal status (N stage). Models 
2–6 included combinations of the CCI (comorbidity) and 
SCARF index (frailty) as measures of biological age and 
chronological age at diagnosis.
The association between the SCARF index and survival 
was evaluated using a series of Cox proportional hazards 
models that used the same six combinations of variables. 
Women who received surgery for ER- positive EIBC have 
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Figure 1 Proportion of women receiving surgery for ER- 
positive early invasive breast cancer in England, between 
2014 and 2017.
better survival than women who did not.35 Thus, the 
relationship between survival and surgery was explored 
by: (1) subgroups of women who did and did not have 
surgery and (2) using surgery as an explanatory variable 
in a Cox proportional hazards model for all women. 
The study specifically focused on 3- year survival because 
recommendations by the International Society of Geri-
atric Oncology and European Society of Breast Cancer 
Specialists for older women with breast cancer state that 
‘primary endocrine therapy (PET) should only be offered to 
elderly individuals with ER- positive tumours who have a short 
estimated life- expectancy (<2–3 years), who are considered unfit 
for surgery after optimization of medical conditions…’.36
The performance of the models was evaluated in 
terms of their discrimination using Harrell’s c- statistic,37 
which corresponds to the area under the curve. A c- sta-
tistic value of 0.5 indicates that the model’s discrimina-
tive power is similar to chance, and 1.0 suggests perfect 
model discrimination. Their relative performance was 
also assessed using decision curve analysis (DCA). This 
method is based on evaluating the ‘net- benefit’ of model 
predictions across of range of possible decision thresh-
olds that reflect how a patient might weigh the risk of 
harm associated with a false positive result (compared 
with a true positive result).38 39 Models with a better 
performance have a greater net benefit across all thresh-
olds of probability.
A similar methodology was applied to externally vali-
date the SCARF index using data on women diagnosed 
in Wales. Analyses were conducted using Stata V.15.1. All 
statistical tests were two sided.
results
Frailty index development and internal validation
The study cohort for England contained 67 925 women 
aged ≥50 years diagnosed with unilateral ER- positive 
EIBC between 1 January 2014 and 31 December 2017. 
Their clinical and pathological characteristics at diagnosis 
are summarised by age group in table 1. The majority 
of women had grade 2, HER2- negative EIBC with no 
regional lymph node involvement (N0) and the propor-
tion of women who presented with larger tumours (21–50 
mm, T2) increased with age.
The development process resulted in an index 
containing 32 deficits defined using used 356 ICD-10 
codes (online supplementary table 1). The initial review 
identified potential diagnostic codes for all 36 deficits, 
with the exception of polypharmacy. This deficit was 
therefore dropped because medication prescription 
records are unavailable in HES and PEDW. The evaluation 
of the remaining 35 deficits against the criteria in Box 1 
led to several complementary deficits being grouped 
together (‘housebound’ and ‘requirement for care’) 
and one deficit (‘sleep disturbance’) being dropped due 
to a low prevalence. The mean index and 99th centile 
values for the SCARF index in the English cohort were 
0.05 and 0.30, respectively, and had positive correlation 
with the CCI (r=0.76). The SCARF index also revealed 
an increasing burden of frailty across the CGA domains 
(problems with cognition/mood, nutrition or ability to 
function daily, geriatric syndromes and comorbidity),6 
with older age (online supplementary table 2).
Association of the sCArF index with likelihood of surgery
Among the 67 975 women with ER- positive EIBC, 61 813 
(91%) underwent surgery. The rate of surgery decreased 
with older age (figure 1), but age was only one of the 
patient and tumour factors associated with the likelihood 
of not receiving surgery (table 2). When considered in 
separate models, greater burden of comorbidity (model 
2) or frailty (model 3) increased the likelihood of women 
not receiving surgery. Both these factors remained 
predictors after baseline tumour factors and chrono-
logical age were accounted for. In particular, frailty was 
more strongly associated with reduced likelihood of 
receiving surgery compared with comorbidity (models 4 
and 6). The model that included comorbidity and frailty 
as biological age measures together with chronological 
age had the greatest discrimination, with a c- statistic of 
0.858 (table 2, model 6). A similar pattern of improving 
performance is shown in the results of the decision curve 
analysis (figure 2). All models had a greater net benefit 
than the two default decision strategies of no women or 
all women having surgery, but there was considerable 
improvement when the biological age factors (frailty 
and comorbidity) were included to the models (with or 
without chronological age).
Association of the sCArF index with survival
The survival analysis had a median follow- up of 35 months 
(IQR: 24 and 46 months). Irrespective of age, the rate of 
early death was higher among women who did not have 
surgery compared with those who did (figure 3). In both 
circumstances, older chronological age and high- risk 
tumour characteristics, such as higher grade and pres-
ence of nodal metastasis, were predictive of worse 3- year 
overall survival (model 5). The inclusion of biological age 
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Figure 2 Decision curve for likelihood of not receiving 
surgery for ER- positive EIBC in England: a comparison 
of models with tumour factors and deprivation status 
only (model 1) and models with the addition of Charlson 
Comorbidity Index (CCI) (model 2), secondary care 
administrative records frailty (SCARF) index (model 3), CCI 
and SCARF index (model 4), chronological age only (model 5) 
and CCI, SCARF index and age (model 6).
Figure 3 Observed survival for women with ER- positive 
EIBC diagnosed between 2014 and 2017 in England by 
age group at diagnosis and receipt of surgery. EIBC, early 
invasive breast cancer.
measures (model 6) improved the model performance, 
increasing the c- statistic from 0.750 to 0.770 in women 
who had surgery and from 0.638 to 0.663 in women who 
did not have surgery and from 0.843 to 0.852 in all women 
(table 3). Similar to previous, this full model (model 6) 
demonstrated the best discrimination. In the DCA, model 
6 with both measures of biological and chronological age 
again produced the best overall performance (figure 4).
Table 4 describes the relationships between overall 
survival and the tumour and patient factors for women 
with ER- positive EIBC as estimated in model 6. As 
expected, worse survival was associated with high- risk 
tumour characteristics (eg, higher grade and presence 
of nodal metastasis), a burden of comorbidity or frailty, 
advanced age and not having surgery.
external validation of the sCArF index
The cohort of Welsh patients consisted of 4 230 women 
aged ≥50 years, diagnosed with unilateral ER- positive 
EIBC between January 2014 and December 2017. The 
median age was 66 years (range 50–100): 64% (n=2 812) 
were aged 50–69 years, 22% (n=984) were aged 70–79 
years and 14% (n=434) were aged ≥80 years. Baseline 
patient and tumour characteristics were similar between 
the English and Welsh cohorts (table 1). Specifically, 
although the calculations of the CCI and SCARF index 
for Welsh patients could only use records with 14 diag-
nostic fields (compared with the 20 diagnostic fields in 
HES), there was a similar prevalence of comorbidity and 
frailty in the two cohorts. The mean SCARF index and 
99th centile values were 0.03 and 0.31, respectively.
There were 3 913 (93%) Welsh women who received 
surgical treatment for EIBC. The associations between 
the tumour and patient factors and the likelihood of a 
woman not having surgery were similar to those observed 
in English cohort (online supplementary table 3). In 
particular, the inclusion of biological age factors (comor-
bidity and frailty) and chronological age in a model 
improved the ability of the model to discriminate between 
women who did and did not receive surgery (corre-
sponding increase in c- statistic from 0.830 in model 5, to 
0.848 in model 6). A similar effect was observed for the 
overall survival of the women diagnosed in Wales (corre-
sponding increase in c- statistic from 0.837 in model 5, to 
0.841 for model 6) (table 3).
DIsCussIOn
Frailty is a commonly used descriptor of biological age in 
research studies, but measurements of frailty have yet to 
be incorporated in routinely collected healthcare data.12 
This study describes the construction of the SCARF index 
based on the widely adopted cumulative deficits model 
of frailty, as used in the eFI15 and CHSA frailty index.40 
The SCARF index was designed for use in analyses of 
population- level cancer registration data and can also 
be used in hospital administrative datasets. In this popu-
lation of women with breast cancer, the index demon-
strated good face validity by producing the expected 
increasing prevalence of frailty among older patients, 
both overall and within the CGA domains. It also demon-
strated a strong association with both patterns of surgical 
practice and patient survival when added to models that 
also contained age and comorbidity.
Standardising methods to measure frailty is particularly 
important to reliably estimate the prevalence of frailty 
and to understand its influence on treatment patterns 
and outcomes. This study focused on women with breast 
cancer because it is the most common type of female 
cancer, and older chronological age is a well- established 
risk- factor for disease development.41 The majority of 
women present with early stage breast cancer3 and while 
this may represent a low- risk group with respect to their 
breast cancer, the cohort would contain the typical 
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Table 3 Harrell’s c- statistic for discrimination ability of Cox proportional hazards models on 3- year overall survival of women 
aged 50+ years with ER- positive EIBC by country of diagnosis
Model 
no.
Factors included in the cox regression model for 3 year 
survival
Harrell’s c- statistic for cox proportional hazards survival model
England (internal validation) Wales (external validation)
In all 
women*
In women who 
did receive 
surgery
In women who 
did not receive 
surgery
In all 
women*
In women who 
did receive 
surgery
In women who 
did not receive 
surgery
1 Invasive grade, T stage, N stage, HER2 status, IMD status
(+receipt of surgery*)
0.804 0.669 0.552 0.782 0.634 0.653
2 Invasive grade, T stage, N stage, HER2 status, IMD status+CCI 
(+receipt of surgery*)
0.824 0.708 0.618 0.802 0.664 0.679
3 Invasive grade, T stage, N stage, HER2 status, IMD 
status+SCARF index (+receipt of surgery*)
0.828 0.718 0.625 0.804 0.667 0.691
4 Invasive grade, T stage, N stage, HER2 status, IMD 
status+CCI+SCARF index (+receipt of surgery*)
0.829 0.719 0.628 0.805 0.673 0.690
5 Invasive grade, T stage, N stage, HER2 status, IMD status+age 
(+receipt of surgery*)
0.842 0.750 0.638 0.837 0.723 0.703
6 Invasive grade, T stage, N stage, HER2 status, IMD 
status+CCI+SCARF index+age (+receipt of surgery*)
0.852 0.770 0.663 0.841 0.734 0.715
*The receipt of surgery was only factored in the model that included all women.
CCI, Charlson Comorbidity Index; EIBC, early invasive breast cancer; HER2, Human epidermal growth factor receptor 2; IMD, Index for multiple deprivation; SCARF, secondary care administrative records 
frailty.
Figure 4 Decision curve for likelihood of survival in women 
who did and who did not receive surgery for ER- positive 
EIBC in England: comparison of models with tumour 
characteristics only (model 1) and models with the addition of 
Charlson Comorbidity Index (CCI) (model 2), secondary care 
administrative records frailty (SCARF) index (model 3), CCI 
and SCARF index (model 4), chronological age only (model 
5) and CCI, SCARF index and age (model 6). EIBC, early 
invasive breast cancer.
spectrum of frailty seen among older women. In addi-
tion, breast cancer trials that focus on older women are 
often unsuccessful due to poor accrual,42 thus routinely 
collected data are an increasingly valuable research 
resource in this population.
Surgical resection is the standard of care for women 
with EIBC.43 Specifically, in women with ER- positive 
EIBC, surgery offers survival outcomes that are superior 
to primary endocrine therapy.35 However, variation in 
the rate of primary surgery and survival, between older 
and younger women with ER- positive EIBC is widely 
reported.1 2 35 44 The ability to distinguish between comor-
bidity and frailty is clinically relevant because these 
factors can be optimised, and potentially reversed (in the 
case of frailty), to improve rates of surgery and survival 
in women with EIBC. Another benefit of assessing frailty 
might also be the identification of older women who are 
sufficiently fit to be offered more aggressive breast cancer 
treatments. In time, we expect that an appropriate frailty 
instrument will be adopted within clinical practice, the 
results of which could be entered into cancer registra-
tion datasets.45 However, until then, population- based 
analyses that use national cancer datasets will be limited 
to using tools like the SCARF index to improve under-
standing of the influence of frailty on treatment patterns 
and survival. This is important for improving the quality 
of breast cancer care and for the education of health 
professionals. Clinicians can be inconsistent in estimating 
the life expectancy of older women with a higher burden 
of comorbidity and frailty, which subsequently influences 
their willingness to advocate surgery for these women.46
There are several strengths to this study. First, the SCARF 
index was constructed using solely ICD-10 diagnosis codes 
and can therefore be widely applied to other population 
level datasets. Moreover, the index produced similar 
results from using data from HES and PEDW although 
they differed in the number of available diagnostic fields 
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Table 4 Cox proportional hazards survival analysis (model 6) for 3- year overall survival in women aged ≥50 years with ER- 
positive early invasive breast cancer in England between 2014 and 2017
Total number of 
women
% women alive at 
3 years Adjusted OR 95% CI P value
Age at diagnosis (years) 67 925 94 1.06 1.05 to 1.06 <0.001
Invasive grade
  G1 13 352 96 1 <0.001
  G2 40 999 94 1.05 0.96 to 1.16
  G3 13 574 91 1.64 1.47 to 1.83
Tumour size (T stage)
  1–20 mm (T0–1) 41 225 95 1 <0.001
  21–50 mm (T2) 23 974 90 1.31 1.22 to 1.41
  51+mm (T3) 2 726 89 1.69 1.48 to 1.93
Nodal metastasis (N- stage)
  N0 49 837 94 1 <0.001
  N1 15 594 93 1.39 1.29 to 1.50
  N2 2 494 89 2.16 1.88 to 2.49
HER2 status
  Positive 6 271 92 1 <0.001
  Negative 56 564 94 0.81 0.73 to 0.90
  Borderline 5 090 92 0.82 0.71 to 0.95
Deprivation status
  1 (most deprived) 10 065 91 1 <0.001
  2 12 131 93 0.86 0.78 to 0.95
  3 14 137 94 0.74 0.67 to 0.82
  4 15 998 94 0.77 0.70 to 0.85
  5 (least deprived) 15 594 95 0.67 0.61 to 0.75
Charlson Comorbidity Index
  0 58 488 96 1 <0.001
  1 6 259 87 1.25 1.11 to 1.40
  2 2 057 77 1.41 1.22 to 1.62
  3+ 1 121 59 1.86 1.59 to 2.18
Secondary care administrative records frailty index index
  Fit 53 800 96 1 <0.001
  Mild frailty 7 501 92 1.22 1.09 to 1.36
  Moderate frailty 4 498 82 1.44 1.27 to 1.64
  Severe frailty 2 126 61 1.63 1.41 to 1.89
Surgery
  No 6 112 64 1 <0.001
  Yes 61 813 96 0.21 0.20 to 0.23
*P value from z- test for continuous variables and Wald test for categorical variables.
(20 and 14, respectively). Second, the deficits within 
the SCARF index were based on those contained in two 
widely used frailty indices (eFI and CHSA) that have been 
validated using community populations. Last, the study 
demonstrated how the influences of chronological and 
biological age measures improve the explanatory power 
of models for two important patient outcomes.
There are also some study limitations. First, calculating 
the SCARF index relies on the accurate coding of patient 
diagnoses within administrative datasets. Conditions such 
as pressure ulcers and urinary incontinence were previ-
ously poorly recorded in administrative datasets, but 
there has been improvement in data quality over time 
and during the study period.47 The SCARF index also 
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demonstrated an increasing prevalence of frailty with age, 
both as an overall score and within the CGA domains, 
which are similar to previous reports. Second, the calcula-
tions of the SCARF index deficits used data from 2 years 
prior to the date of diagnosis. This method is similar to 
published studies18 and unavoidable due to the static 
nature of administrative data. Given the potentially revers-
ible nature of frailty, this might introduce some misclas-
sification error. Third, the SCARF index was constructed 
using data from a female cohort with ER- positive EIBC. 
The study was restricted to describing frailty within a 
specific disease rather than the general population. 
Nonetheless, this study uses a method of index construc-
tion that has proven effective in many other population 
groups, and there is no reason to suspect the SCARF 
index measures a condition- specific form of frailty. We 
note that the widely used CCI was initially developed in a 
cohort of women with primary breast cancer.48 Finally, the 
results were based on a complete case analysis, with 6.5% 
of records dropped because they could not be linked 
to a HES/PEDW record and another 8.8% of records 
dropped because of missing values (mostly related to 
missing HER2 status (8.6%)). This might introduce bias 
in the observed relationship between the SCARF index 
and the outcomes, but the effect is likely to be small. 
The distributions of age at diagnosis were similar among 
included and excluded patients, suggesting the analysis 
cohort retained a full spectrum of frailty.
It is important that further work is undertaken to 
extend the evaluation of the SCARF index. This includes 
the application of this index on different cohorts of 
patients with breast cancer or another cancer to examine 
the influence of frailty on disease presentation and 
uptake of adjuvant therapies. Future work also includes 
assessing the agreement between the SCARF index and 
other frailty assessment tools. One option is to compare it 
against the Clinical Frailty Scale,3 which will become part 
of routinely collected breast cancer data in England from 
2020.45 Opportunities to triangulate between measures 
of frailty using hospital level (SCARF index) and primary 
care level data (eFI) should also be explored.
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